Xeris Biopharma (NASDAQ:XERS) Research Coverage Started at Oppenheimer

Investment analysts at Oppenheimer started coverage on shares of Xeris Biopharma (NASDAQ:XERS - Get Free Report) in a note issued to investors on Thursday, Marketbeat.com reports. The brokerage set an "outperform" rating and a $5.00 price target on the stock. Oppenheimer's price objective would indicate a potential upside of 126.24% from the stock's current price.

Separately, HC Wainwright raised their price target on Xeris Biopharma from $5.50 to $6.00 and gave the company a "buy" rating in a research report on Thursday, March 7th.

Xeris Biopharma Stock Up 8.3 %

NASDAQ XERS traded up $0.17 during trading on Thursday, hitting $2.21. 3,220,772 shares of the company traded hands, compared to its average volume of 2,376,365. Xeris Biopharma has a 12 month low of $1.31 and a 12 month high of $3.26. The business has a fifty day simple moving average of $2.62 and a 200 day simple moving average of $2.19. The company has a current ratio of 1.64, a quick ratio of 1.23 and a debt-to-equity ratio of 49.27. The company has a market capitalization of $310.39 million, a P/E ratio of -4.93 and a beta of 2.37.

Xeris Biopharma (NASDAQ:XERS - Get Free Report) last posted its earnings results on Wednesday, March 6th. The company reported ($0.10) earnings per share for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Xeris Biopharma had a negative net margin of 37.98% and a negative return on equity of 610.76%. The company had revenue of $44.39 million for the quarter, compared to the consensus estimate of $45.50 million. During the same quarter last year, the business earned ($0.10) earnings per share. As a group, sell-side analysts predict that Xeris Biopharma will post -0.37 EPS for the current year.

Institutional Investors Weigh In On Xeris Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its position in Xeris Biopharma by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 7,086,345 shares of the company's stock worth $16,653,000 after buying an additional 60,181 shares in the last quarter. Goldman Sachs Group Inc. grew its position in Xeris Biopharma by 94.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 258,689 shares of the company's stock worth $608,000 after buying an additional 125,849 shares in the last quarter. Quarry LP acquired a new stake in Xeris Biopharma during the fourth quarter worth about $47,000. GSA Capital Partners LLP grew its position in Xeris Biopharma by 9.2% during the fourth quarter. GSA Capital Partners LLP now owns 416,267 shares of the company's stock worth $978,000 after buying an additional 35,036 shares in the last quarter. Finally, Barclays PLC grew its position in Xeris Biopharma by 161.0% during the fourth quarter. Barclays PLC now owns 275,963 shares of the company's stock worth $648,000 after buying an additional 170,220 shares in the last quarter. 42.75% of the stock is owned by institutional investors and hedge funds.

About Xeris Biopharma

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.